GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Intangible Assets

Apollon Formularies (AQSE:APOL) Intangible Assets : £0.00 Mil (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Apollon Formularies's intangible assets for the quarter that ended in Jun. 2023 was £0.00 Mil.


Apollon Formularies Intangible Assets Historical Data

The historical data trend for Apollon Formularies's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Intangible Assets Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.38 -

Apollon Formularies Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Apollon Formularies  (AQSE:APOL) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Apollon Formularies Intangible Assets Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC

By Jimmy Xiao gurujx 05-17-2015

FPA Capital Fund 4th Quarter 2015 Commentary

By Holly LaFon Holly LaFon 02-08-2016

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

Jeff Auxier Interview with GuruFocus

By Holly LaFon Holly LaFon 08-28-2012

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 02-19-2015

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015

6 Highly Predictable Companies with Historically Low P/S Ratios

By Dianne Tordillo Dianne Tordillo 11-27-2012

First Pacific Advisors Buys Alcoa, Bank of America

By Tiziano Frateschi Tiziano Frateschi 10-16-2015

FPA Capital Fund Comments on Apollo Education Group

By Holly LaFon Holly LaFon 02-09-2016